ArQule (ARQL) and Its Competitors Head-To-Head Analysis

ArQule (NASDAQ: ARQL) is one of 198 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare ArQule to similar companies based on the strength of its institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and earnings.

Valuation and Earnings

This table compares ArQule and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
ArQule $2.41 million -$26.76 million -2.59
ArQule Competitors $207.79 million -$2.30 million 0.50

ArQule’s competitors have higher revenue and earnings than ArQule. ArQule is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ArQule and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ArQule 0 0 0 0 N/A
ArQule Competitors 481 2271 6203 119 2.66

As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.19%. Given ArQule’s competitors higher probable upside, analysts plainly believe ArQule has less favorable growth aspects than its competitors.

Volatility & Risk

ArQule has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, ArQule’s competitors have a beta of 1.63, suggesting that their average stock price is 63% more volatile than the S&P 500.

Institutional & Insider Ownership

61.0% of ArQule shares are owned by institutional investors. Comparatively, 46.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 9.0% of ArQule shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares ArQule and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ArQule N/A -135.68% -77.68%
ArQule Competitors -3,963.67% -118.29% -43.76%


ArQule competitors beat ArQule on 7 of the 9 factors compared.

ArQule Company Profile

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company’s lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company’s product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with's FREE daily email newsletter.

Leave a Reply